Company intelligence / Profile preview

Pet2DAO

Agoura Hills, California, United States

Ownership: Private
Development stage: Other

Overview

Pet2DAO is a wholly owned subsidiary of Oncotelic Therapeutics, established in late 2022, that operates a decentralized autonomous organization (DAO) structure using blockchain and AI technologies. Its PDAOAI platform has demonstrated utility in life sciences, notably by streamlining GMP compliance and supporting pharmaceutical and biotech operations, but does not develop therapeutics or run clinical trials itself.[1][3][4][5][7][10]

Industry: Biomedical IT and Biomedical Data Platforms

Beyond the preview

Go deeper on Pet2DAO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pet2DAO.

Explore the full profile